FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3039209319> ?p ?o ?g. }

• W3039209319 endingPage "104721" @default.
• W3039209319 startingPage "104721" @default.
• W3039209319 abstract "All cosmetic products placed onto the market must undergo a risk assessment for human health to ensure they are safe for consumers, including an assessment of skin sensitisation risk. Historically, in vivo animal test methods were used to identify and characterise skin sensitisation hazard, however non-animal and other new approach methodologies (NAMs) are now the preferred and mandated choice for use in risk assessment for cosmetic ingredients. The experience gained over the last three decades on how to conduct risk assessments based upon NAMs has allowed us to develop a non-animal, next generation risk assessment (NGRA) framework for the assessment of skin sensitisers. The framework presented here is based upon the principles published by the International Cooperation on Cosmetic Regulation (ICCR) and is human relevant, exposure led, hypothesis driven and designed to prevent harm. It is structured in three tiers and integrates all relevant information using a weight of evidence (WoE) approach that can be iterated when new information becomes available. The initial tier (TIER 0) involves a thorough review of the existing information including; identification of the use scenario/consumer exposure; characterisation of the chemical purity and structure; in silico predictions; existing data pertaining to skin sensitisation hazard (historical or non-animal); the identification of suitable read-across candidates with supporting hazard identification/characterisation information and application of exposure-based waiving. Considering all information identified in TIER 0, the next step is the generation of a hypothesis (TIER 1). All data are considered in an exposure-led WoE approach, taking into account an initial view on whether a chemical is likely to be a skin sensitiser or not, choice of defined approach (DA) and availability of read-across candidates. If existing information is insufficient for concluding the risk assessment, the generation of additional information may be required to proceed (TIER 2). Such targeted testing could involve refinement of the exposure estimation or generation of data from in vitro or in chemico NAMs. Once sufficient information is available, the final stage of the NGRA framework is the determination of a point of departure (POD), characterising uncertainty and comparing to the consumer exposure in a WoE. Thorough evaluation of the sources of uncertainty is essential to ensure transparency and build trust in new risk assessment approaches. Although significant progress has been made, industry must continue to share its experience in skin sensitisation NGRA via case studies to demonstrate that this new risk assessment approach is protective for consumers. Dialogue and collaboration between key stakeholders, i.e. risk assessors, clinicians and regulators are important to gain mutual understanding and grow confidence in new approaches." @default.
• W3039209319 created "2020-07-10" @default.
• W3039209319 creator A5003012755 @default.
• W3039209319 creator A5019547212 @default.
• W3039209319 creator A5023026500 @default.
• W3039209319 creator A5027438053 @default.
• W3039209319 creator A5028271004 @default.
• W3039209319 creator A5031592925 @default.
• W3039209319 creator A5033346490 @default.
• W3039209319 creator A5043226310 @default.
• W3039209319 creator A5043482117 @default.
• W3039209319 creator A5050446245 @default.
• W3039209319 creator A5067443701 @default.
• W3039209319 creator A5073553852 @default.
• W3039209319 creator A5076546186 @default.
• W3039209319 creator A5076757334 @default.
• W3039209319 creator A5078710727 @default.
• W3039209319 creator A5083087111 @default.
• W3039209319 creator A5085642022 @default.
• W3039209319 creator A5051899360 @default.
• W3039209319 date "2020-10-01" @default.
• W3039209319 modified "2023-10-14" @default.
• W3039209319 title "Development of a next generation risk assessment framework for the evaluation of skin sensitisation of cosmetic ingredients" @default.
• W3039209319 cites W1526255487 @default.
• W3039209319 cites W1570912112 @default.
• W3039209319 cites W162582067 @default.
• W3039209319 cites W17068368 @default.
• W3039209319 cites W1718770430 @default.
• W3039209319 cites W1753071495 @default.
• W3039209319 cites W1897876044 @default.
• W3039209319 cites W1966327639 @default.
• W3039209319 cites W1966653862 @default.
• W3039209319 cites W1970327537 @default.
• W3039209319 cites W1974918761 @default.
• W3039209319 cites W1976477992 @default.
• W3039209319 cites W1979636993 @default.
• W3039209319 cites W1982341434 @default.
• W3039209319 cites W1983404175 @default.
• W3039209319 cites W1984172495 @default.
• W3039209319 cites W1987746722 @default.
• W3039209319 cites W1990878286 @default.
• W3039209319 cites W1991465136 @default.
• W3039209319 cites W1992110036 @default.
• W3039209319 cites W1992445582 @default.
• W3039209319 cites W1993795069 @default.
• W3039209319 cites W1994087025 @default.
• W3039209319 cites W1994122604 @default.
• W3039209319 cites W1994946264 @default.
• W3039209319 cites W1998816898 @default.
• W3039209319 cites W1999157594 @default.
• W3039209319 cites W2003237056 @default.
• W3039209319 cites W2004590673 @default.
• W3039209319 cites W2010609085 @default.
• W3039209319 cites W2012663457 @default.
• W3039209319 cites W2013748147 @default.
• W3039209319 cites W2014022917 @default.
• W3039209319 cites W2019206282 @default.
• W3039209319 cites W2022774320 @default.
• W3039209319 cites W2031778481 @default.
• W3039209319 cites W2039183761 @default.
• W3039209319 cites W2039767238 @default.
• W3039209319 cites W2043976293 @default.
• W3039209319 cites W2044733423 @default.
• W3039209319 cites W2050092045 @default.
• W3039209319 cites W2054865262 @default.
• W3039209319 cites W2056430003 @default.
• W3039209319 cites W2057788751 @default.
• W3039209319 cites W2072247425 @default.
• W3039209319 cites W2077343145 @default.
• W3039209319 cites W2087926902 @default.
• W3039209319 cites W2089734502 @default.
• W3039209319 cites W2090321152 @default.
• W3039209319 cites W2091154477 @default.
• W3039209319 cites W2093905790 @default.
• W3039209319 cites W2110096713 @default.
• W3039209319 cites W2117809365 @default.
• W3039209319 cites W2140461696 @default.
• W3039209319 cites W2156187464 @default.
• W3039209319 cites W2157971131 @default.
• W3039209319 cites W2161355010 @default.
• W3039209319 cites W2168962592 @default.
• W3039209319 cites W2171517828 @default.
• W3039209319 cites W2176596140 @default.
• W3039209319 cites W2177324949 @default.
• W3039209319 cites W2270295941 @default.
• W3039209319 cites W2280309383 @default.
• W3039209319 cites W2314606706 @default.
• W3039209319 cites W2319741579 @default.
• W3039209319 cites W2336085680 @default.
• W3039209319 cites W2339053976 @default.
• W3039209319 cites W2344893489 @default.
• W3039209319 cites W2464316836 @default.
• W3039209319 cites W2486585148 @default.
• W3039209319 cites W2495307734 @default.
• W3039209319 cites W2514134638 @default.
• W3039209319 cites W2519334767 @default.
• W3039209319 cites W2525853680 @default.
• W3039209319 cites W2534809788 @default.

• next